Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Sarepta Therapeutics's SRP-5051?
SRP-5051 is an antisense oligonucleotide commercialized by Sarepta Therapeutics, with a leading Phase II program in Duchenne Muscular Dystrophy. According...